Curia

Partnering with a single CDMO can increase speed to market, ensure production capacity and avoid costly-time consuming tech transfers. Learn more inside this eBook.

The combination of the PentaMice® platform and single B cell screening with the Beacon® system increases speed to market for monoclonal antibody antibody therapeutics.

Curia's CHO-GSN™ platform is a stable cell line development service maximizing purity and yield.

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate can be daunting. This white paper details how to optimize formulation development and tech transfer to ensure successful biologics production.

End-to-end contract research, development and manufacturing services for large and small molecules.